S. Ono

发表

Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients.

H. Yabe, A. Suzuki, S. Kaneko, 2002, Pharmacology & toxicology.

Association between Taq1 a dopamine D2 receptor polymorphism and psychopathology of schizophrenia in Japanese patients

K. Otani, A. Suzuki, S. Kaneko, 2000, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin.

K. Otani, S. Kaneko, T. Kondo, 2000, Journal of clinical psychopharmacology.

Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.

K. Otani, A. Suzuki, S. Kaneko, 2000, Therapeutic drug monitoring.

Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients

K. Otani, A. Suzuki, S. Kaneko, 2001 .

Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients.

K. Otani, A. Suzuki, S. Kaneko, 2008, Pharmacology & toxicology.

Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes

A. Suzuki, S. Kaneko, R. de Vries, 2002, Psychopharmacology.

Effect of Dietary Fat Content in Meals on Pharmacokinetics of Quazepam

S. Kaneko, T. Kondo, T. Takahata, 2002, Journal of clinical pharmacology.

Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs

K. Otani, A. Suzuki, S. Kaneko, 2002 .

Dopamine D2 receptor gene polymorphisms and clinical response to selective dopamine receptor antagonists

K. Otani, S. Kaneko, T. Kondo, 2002 .

Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol.

T. Kondo, K. Otani, A. Suzuki, 2001, American journal of medical genetics.

No relationship between −141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study

K. Otani, A. Suzuki, S. Kaneko, 2001, Psychiatry Research.

No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study.

T. Kondo, K. Otani, A. Suzuki, 2000, American journal of medical genetics.

Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin

S. Kaneko, T. Kondo, N. Tokinaga, 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene

K. Otani, A. Suzuki, S. Kaneko, 2000, Psychopharmacology.

Relationship Between Plasma Concentrations of Trazodone and Its Active Metabolite, m-Chlorophenylpiperazine, and Its Clinical Effect in Depressed Patients

K. Otani, S. Kaneko, T. Kondo, 2002, Therapeutic drug monitoring.

Effects of Various CYP2D6 Genotypes on the Steady-State Plasma Concentrations of Risperidone and Its Active Metabolite, 9-Hydroxyrisperidone, in Japanese Patients With Schizophrenia

T. Iga, N. Yasui-Furukori, Y. Takarada, 2003, Therapeutic drug monitoring.

Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatmentresistance to dopamine receptor antagonists in schizophrenic patients

A. Suzuki, S. Kaneko, T. Kondo, 2003 .

Effect of CYP2D6 genotype on pharmacokinetic interactions with psychotropic drugs

A. Suzuki, S. Kaneko, T. Kondo, 2002 .

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome

K. Otani, A. Suzuki, S. Kaneko, 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Formulations of Valproate Alter Valproate Metabolism: A Single Oral Dose Kinetic Study

T. Kondo, K. Mihara, S. Ono, 2009, Therapeutic drug monitoring.